RankAlpha logo
Back to Rankings

DFTX

Definium TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The positive case is that DFTX has one of the cleaner late-stage psychiatric development setups in small-cap biotech: a fully enrolled first Phase 3 MDD study, a second Phase 3 MDD study moving forward, additional GAD framing around DT120, and cash, cash equivalents, and investments of about $411.6 million at December 31, 2025 that management says should fund operations into 2028 [#10-K-2026-02-26]. If April messaging de-risks the path to late-Q2 data and the Emerge readout is supportive, the shares can move materially toward the existing median target neighborhood.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.1.
What can break
Despite runway into 2028 per the 10-K, prolonged development setbacks could eventually force a lower-quality financing outcome.
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $34.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-20 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $57.80
Why
Momentum100 · Δ7d +0.1
Value41 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+1.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade D. Momentum 99.7 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$5.98B
Beta
2.62
Shares Out
132.74M
P/E (TTM) · Derived
-21.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-29.60
Rev YoY
-
EPS YoY
+158.2%
Gross Margin
-
Op Margin
-
Net Debt
-$371.01M
Current Ratio
4.69
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology